Sequoia Financial Advisors LLC Raises Stock Holdings in The Cooper Companies, Inc. $COO

by · The Cerbat Gem

Sequoia Financial Advisors LLC increased its holdings in The Cooper Companies, Inc. (NASDAQ:COO – Free Report) by 290.4% in the 2nd quarter, Holdings Channel reports. The fund owned 34,286 shares of the medical device company’s stock after buying an additional 25,504 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Cooper Companies were worth $2,459,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Tidal Investments LLC increased its holdings in shares of Cooper Companies by 281.4% during the second quarter. Tidal Investments LLC now owns 82,903 shares of the medical device company’s stock valued at $5,945,000 after acquiring an additional 61,165 shares in the last quarter. National Pension Service raised its holdings in shares of Cooper Companies by 9,314.0% during the second quarter. National Pension Service now owns 526,149 shares of the medical device company’s stock valued at $37,730,000 after purchasing an additional 520,560 shares during the last quarter. WINTON GROUP Ltd lifted its holdings in shares of Cooper Companies by 379.0% during the 2nd quarter. WINTON GROUP Ltd now owns 42,483 shares of the medical device company’s stock valued at $3,046,000 after buying an additional 33,613 shares during the period. Engineers Gate Manager LP lifted its holdings in Cooper Companies by 8,637.7% in the second quarter. Engineers Gate Manager LP now owns 249,897 shares of the medical device company’s stock valued at $17,920,000 after acquiring an additional 247,037 shares during the period. Finally, NewEdge Advisors LLC lifted its stake in shares of Cooper Companies by 286.2% in the 2nd quarter. NewEdge Advisors LLC now owns 12,780 shares of the medical device company’s stock worth $916,000 after purchasing an additional 9,471 shares during the period. Institutional investors own 24.39% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on COO shares. KeyCorp reaffirmed a “sector weight” rating on shares of Cooper Companies in a report on Friday, June 5th. Citigroup restated a “neutral” rating and set a $60.00 target price (down from $80.00) on shares of Cooper Companies in a research report on Thursday. Robert W. Baird set a $61.00 price target on Cooper Companies and gave the company a “neutral” rating in a research note on Thursday. Bank of America reissued a “neutral” rating and issued a $65.00 price objective (down from $80.00) on shares of Cooper Companies in a research note on Thursday. Finally, Stifel Nicolaus set a $70.00 target price on Cooper Companies and gave the stock a “buy” rating in a report on Thursday. Five research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Cooper Companies has a consensus rating of “Hold” and a consensus target price of $71.47.

Check Out Our Latest Stock Analysis on Cooper Companies

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

  • Positive Sentiment: Cooper reported adjusted fiscal Q3 earnings of $1.15 per share, ahead of the approximately $1.11–$1.12 consensus, with earnings up from $0.49 a year earlier. Cost controls and continued fertility-related growth helped offset weakness elsewhere. Cooper Companies Bets on Fertility Growth Despite Weakness in CooperVision
  • Positive Sentiment: The board authorized an additional $1 billion of repurchases, bringing the total buyback authorization to $3 billion. The program could support per-share earnings and signal management believes COO shares are undervalued. Cooper Outlines Q4 EPS and Adds to Buyback Authorization
  • Neutral Sentiment: Cooper completed a strategic review but chose not to pursue a sale or separate transaction for CooperSurgical. Keeping the business preserves its fertility-growth opportunity, but investors had apparently anticipated a potential deal or value-unlocking action. Cooper Cos. Stock Drops After Soft Outlook and No Deal
  • Negative Sentiment: Revenue rose only about 1% to $1.066 billion, missing the roughly $1.10 billion consensus. U.S. channel destocking and inventory reductions pressured CooperVision, raising concerns about near-term demand and sales momentum. COO Q3 Earnings Top Estimates, Revenues Miss on Destocking
  • Negative Sentiment: Management reduced fiscal 2026 earnings guidance to $4.51–$4.55 per share and issued fourth-quarter guidance of $1.05–$1.09, below prior expectations. The weaker outlook triggered multiple analyst downgrades and price-target cuts, including from Baird, UBS, JPMorgan and William Blair.
  • Negative Sentiment: Law firms have announced securities-fraud investigations connected with the post-earnings decline. These notices are often promotional, but they add to negative investor sentiment and potential legal uncertainty. Securities Fraud Investigation Into Cooper Companies Announced

Cooper Companies Price Performance

Shares of COO stock opened at $53.91 on Monday. The Cooper Companies, Inc. has a one year low of $51.01 and a one year high of $89.83. The company has a market capitalization of $10.25 billion, a P/E ratio of 18.40, a P/E/G ratio of 2.19 and a beta of 0.82. The company’s 50-day simple moving average is $71.62 and its two-hundred day simple moving average is $69.61. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73.

Cooper Companies (NASDAQ:COO – Get Free Report) last issued its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. The business had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.Cooper Companies’s revenue was up .5% on a year-over-year basis. During the same period in the previous year, the company posted $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities analysts anticipate that The Cooper Companies, Inc. will post 4.53 EPS for the current year.

Cooper Companies declared that its Board of Directors has approved a share buyback program on Wednesday, September 9th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the medical device company to purchase up to 22.7% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

About Cooper Companies

(Free Report)

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.

Recommended Stories

Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Cooper Companies, Inc. (NASDAQ:COO – Free Report).